Compound Radar

Zoetis Inc. (ZTS) Stock Analysis

Price $73.56
Market cap $30.40B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

74
74/100 High Quality
  • Financial Health 75
  • Profitability 75
  • Business Quality 75
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 74/100 — High Quality

Strongest Cash Flow 80/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Zoetis Inc. (ZTS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Zoetis Inc. 74/100 (High Quality) due to high business quality, manageable leverage, and attractive valuation.

Investment profile

  • Quality High
  • Growth Soft
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 12
  • Forward P/E 11.26
  • EV/Revenue 4.09

Profitability

  • Revenue Growth -0.2%
  • Gross Margin 71.7%
  • Operating Margin 40.7%
  • Net Margin 27.7%
  • ROE 64.9%

Financial strength

  • Cash $1.68B
  • Debt $9.26B
  • Net Cash $-7.58B
  • Free Cash Flow $2.28B
  • Current Ratio 3.08

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Zoetis Inc. (ZTS).

View Methodology & FAQ →